Moexipril

CHEMBL1165 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
498.6 g/mol
LogP
1.2
Phase
4

This ACE inhibitor lowers blood pressure by blocking the enzyme that converts angiotensin I to the potent vasoconstrictor angiotensin II, causing blood vessels to relax and the kidneys to excrete more sodium and water. It is used to treat high blood pressure and may have additional cardiovascular protective effects.

น้ำหนักโมเลกุล

498.6000 g/mol

LogP

1.20

TPSA

114.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O

InChI

InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1

Molecular Formula

C27H34N2O7

HBD / HBA

2 / 8

พันธะที่หมุนได้

12

อะตอมหนัก

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This ACE inhibitor lowers blood pressure by blocking the enzyme that converts angiotensin I to the potent vasoconstrictor angiotensin II, causing blood vessels to relax and the kidneys to excrete more sodium and water. It is used to treat high blood pressure and may have additional cardiovascular protective effects.

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Yes, Moexipril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1165. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 91270. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.